Level D· Scientific groundwork from lab and animal studiesAnimal StudyEurope PMCOpen access

Inhibition of lysophosphatidic acid receptor 1-3 deteriorates experimental autoimmune encephalomyelitis by inducing oxidative stress

Choi JH., Oh J., Lee MJ., Bae H., Ko SG., Nah SY.

Animal Study on Neuroinflammation, Autoimmune Research, published in J Neuroinflammation (2021) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Animal Study
Journal
J Neuroinflammation (2021)
Reported sample size
—
Source database
Europe PMC
PMID
34666785
PMCID
PMC8527776
DOI
10.1186/s12974-021-02278-w
Citations
15

Abstract (original English)

Background Lysophosphatidic acid receptors (LPARs) are G-protein-coupled receptors involved in many physiological functions in the central nervous system. However, the role of the LPARs in multiple sclerosis (MS) has not been clearly defined yet. Methods Here, we investigated the roles of LPARs in myelin oligodendrocyte glycoprotein peptides-induced experimental autoimmune encephalomyelitis (EAE), an animal model of MS. Results Pre-inhibition with LPAR1-3 antagonist Ki16425 deteriorated motor disability of EAE low . Specifically, LPAR1-3 antagonist (intraperitoneal) deteriorated symptoms of EAE low associated with increased demyelination, chemokine expression, cellular infiltration, and immune cell activation (microglia and macrophage) in spinal cords of mice compared to the sham group. This LPAR1-3 antagonist also increased the infiltration of CD4 + /IFN-γ + (Th1) and CD4 + /IL-17 + (Th17) cells into spinal cords of EAE low mice along with upregulated mRNA expression of IFN-γ and IL-17 and impaired blood-brain barrier (BBB) in the spinal cord. The underlying mechanism for negative effects of LPAR1-3 antagonist was associated with the overproduction of reactive oxygen species (ROS)-generating nicotinamide adenine dinucleotide phosphate (NADPH) oxidases (NOX) 2 and NOX3. Interestingly, LPAR1/2 agonist 1-oleoyl-LPA (LPA 18:1) (intraperitoneal) ameliorated symptoms of EAE high and

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
AnimalsMice, Inbred C57BLMiceEncephalomyelitis, Autoimmune, ExperimentalPropionatesIsoxazolesPeptide FragmentsReceptors, Lysophosphatidic AcidOxidative StressDose-Response Relationship, Drug

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research